sellModerate cluster of 3
Bo Kruse sold $723k of YMAB
EVP, CFO, SECRY & TREAS. at Y-mAbs Therapeutics, Inc.. 60,000 shares at an average of $12.05, traded May 30, 2024, filed May 31, 2024.
Warning score
53Value
$723k
60,000 shares
Holdings after
210,877
-25% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +21Trade size$723k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-067356, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 30, 2024 | MOption exercise Common Stock | +28,629 | $2.00 | $57k | 239,506 | May 31, 2024 |
| May 30, 2024 | SOpen-market sale Common Stock | -28,629 | $12.03 | $344k | 210,877 | May 31, 2024 |
| May 31, 2024 | MOption exercise Common Stock | +31,371 | $2.00 | $63k | 242,248 | May 31, 2024 |
| May 31, 2024 | SOpen-market sale Common Stock | -31,371 | $12.07 | $379k | 210,877 | May 31, 2024 |
| May 30, 2024 | MOption exercise Employee Stock Option (right to buy)derivative | -28,629 | $0.00 | $0 | 271,371 | May 31, 2024 |
| May 31, 2024 | MOption exercise Employee Stock Option (right to buy)derivative | -31,371 | $0.00 | $0 | 240,000 | May 31, 2024 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $57k 10,810 shares | -5% | |
| 60Notable | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $1.3M 95,000 shares | -58% | |
| 50Moderate | Y-mAbs Therapeutics, Inc. | Torben Lund-Hansen SVP & CHIEF TECHNICAL OFFICER | $769k 50,000 shares | -58% | |
| 41Moderate | Y-mAbs Therapeutics, Inc. | Joris Wilms SVP & CHIEF OPERATING OFFICER | $73k 5,000 shares | -14% | |
| 40Moderate | Y-mAbs Therapeutics, Inc. | Gerard Ber director | $8,664 722 shares | -31% | |
| 63Notable | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $841k 70,000 shares | -30% | |
| 44Moderate | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $396k 32,351 shares | -12% | |
| 38Weak | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $64k 3,900 shares | -2% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER | $28k 1,682 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.